Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effectiveness of tenofovir alafenamide in reducing clinical events in chronic hepatitis B beyond current guideline indications
KCT0003429Phase 4Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of tenofovir alafenamide in Chronic Hepatitis B (CHB), sponsored by Gilead Sciences. Started Feb 2019; status: active, not recruiting.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on KCT0003429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003429.